Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 4Other hematologic neoplasm 4Lymphoid 3Thoracic 2NET 1Endocrine 1

Conditions

Neoplasms 2Small Cell Lung Carcinoma 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 1152Cisplatin 876Pemetrexed 834pembrolizumab 608Paclitaxel 598Docetaxel 535Gemcitabine 424Radiotherapy 377Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 295durvalumab 254Drug Therapy 233osimertinib 218atezolizumab 208Radiosurgery 190Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 124Magnetic Resonance Spectroscopy 121Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × SNX-5422 × Thoracic × Clear all
NCT01892046 2017-07-26

Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors

Esanex Inc.

Phase 1 Completed
18 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Small Cell Lung Carcinoma

NCT01851096 2016-08-16

Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma

Esanex Inc.

Phase 1 Completed
17 enrolled
Thoracic

Adenocarcinoma of Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡